Cipla to invest in iCaltech to strengthen respiratory play
iCaltech is engaged in the design, development, and commercialisation of diagnostic medical equipment and apparatus
iCaltech is engaged in the design, development, and commercialisation of diagnostic medical equipment and apparatus
Upgrades 2025 full-year CDMO sales and margin outlook
Shelcal Total marks the brand’s evolution into a modern, consumer-focused nutrition portfolio
Reported EBITDA up by 19% year-on-year with reported EBITDA margin at 25%
Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US
This collaboration aims to bridge India’s talent and translational gap in this rapidly growing field by equipping professionals with practical expertise in the manufacturing of advanced therapies.
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
Investment builds on Biogen’s 30-year history of manufacturing in the region, with approximately $10 billion invested to date
Vimta Labs has reported total income of Rs. 99.31 crores during the period ended June 30, 2025
The new Zigly center features and offers comprehensive veterinary services
This achievement underscores our unwavering commitment to upholding the highest standards of quality, safety, and regulatory compliance
Loteprednol Etabonate Ophthalmic Suspension, 0.5% is indicated for the treatment of steroidresponsive inflammatory conditions of the palpebral and bulbar conjunctiva
This marks the fourth acquisition by Corona Remedies from multinational corporations
Enables additional US manufacturing capacity to serve increased demand for pharma/biotech customers
The campaign celebrates radiant, healthy skin that shines naturally, empowering women to step forward with confidence in every walk of life.
Godavari Biorefineries receives patent from CNIPA
The transaction, approved by both companies' boards of directors, is expected to close by the end of the first quarter of 2026
Subscribe To Our Newsletter & Stay Updated